fda warning letter glp-1 october 2025 issues 30 letters to online compounders Prescription Drug Freight Fraud Report,

Mouillot T, Filancia A, Boirie Y, Brindisi MC, Hafnaoui N, Van Wymelbeke V, et al

Dual GLP-1/GIP Receptor Agonists : While clinical evidence is growing for dual-acting therapies, it is a more recent area of development compared to GLP-1 monotherapy

GLP-1 medications do more than help with weight lossthey can meaningfully improve cholesterol levels and triglycerides, reducing your overall cardiovascular risk

Medicare projections under moderate usage scenarios (5% uptake, 20% adherence rate, 30% additional discount) estimate $8 billion in net spending over 10 years

PWS is a well-documented genetic disorder with a characteristic phenotype that includes hyperphagia, leading to obesity if not managed

Hair thinning is another side effect that has gained attention